Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 17/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14504573 | 0.91 | PTGS2 (0.46) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL5152488 | 0.85 | FABP3 (0.45) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL14504805 | 0.84 | PTGS2 (0.46) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL14504928 | 0.83 | PTGS2 (0.47) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL14504559 | 0.82 | PTGS2 (0.70) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL5148876 | 0.82 | PTGS2 (0.37) | CA1CA2CA9PTGS2FABP3 | |
| SCHEMBL14504874 | 0.79 | FABP3 (0.52) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL14504781 | 0.77 | PTGS2 (0.46) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL5147706 | 0.76 | PTGS2 (0.50) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL14504449 | 0.76 | MGLL (0.52) | CA1CA2CA9PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070112037-A1 | Pyrazole Derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183306-B2 | Pyrazole derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112037-A1 | Pyrazole Derivatives | CYP11B2, CYP11B1, CYP3A43 | CA1 4388/4885CA2 3227/4885CA9 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.